Pivotal bioVenture Partners Fund I, L.P.'s Form 4 filing
Inozyme Pharma, Inc. (INZY) · filed Aug 3, 2023
- Accession no.
- 0000950170-23-038272
- Filed
- Aug 3, 2023, 8:13 PM ET
- Trade date
- Aug 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $4.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pivotal bioVenture Partners Fund I, L.P.CIK 0001695076 | Director |
| Pivotal bioVenture Partners Fund I U.G.P. LtdCIK 0001752847 | Director |
| Pivotal bioVenture Partners Fund I G.P., L.P.CIK 0001752862 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | Common Stock | PPurchaseAcquired | +119,048 | $4.80 | +$571,430.4 | 2,923,110 | Indirect | Duplicate filing |
| Aug 1, 2023 | Common Stock | PPurchaseAcquired | +714,285 | $4.80 | +$3,428,568 | 1,571,741 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.